Tivic Health Files Resale Prospectus for 3.1M Shares, Unveils CDMO Arm
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Tivic Health Systems Inc. (NASDAQ: TIVC) is a commercial health technology and immunotherapeutics company headquartered in Hayward, California. Founded in 2016, Tivic develops non-invasive bioelectronic devices and biologic therapies that target the trigeminal, sympathetic, and vagus nerves to treat inflammatory and chronic health conditions without pharmaceuticals.
Corporate structure
According to its 2024 Annual Report, Tivic employs between 11 and 50 people across research, development, manufacturing, and commercial functions. In 2025, the company established a subsidiary, Velocity Bioworks™, to provide Contract Development and Manufacturing Organization (CDMO) services using newly acquired cGMP manufacturing assets.
Bioelectronic medicine by Testalize.me
Recent developments and news
- On December 11, 2025, Tivic filed a Form 8-K reporting multiple corporate updates.
- On December 12, 2025, the company submitted two Rule 424(b)(3) prospectus supplements: one covering the resale of 1,580,437 common shares plus up to 8,400 Series B Non-Voting Convertible Preferred shares and warrants; the other covering 1,592,135 common shares. Four of six tranches under the related Purchase Agreement have closed, and the agreement’s termination date was extended to December 9, 2026. A stockholder meeting is scheduled by March 9, 2026, to approve adjustments to the preferred-stock conversion floor price.
- In 2025, Tivic acquired cGMP manufacturing and development assets from Scorpius Holdings to support the Biologics License Application (BLA) for its TLR5 agonist program, Entolimod™.
- On November 12–13, 2025, CEO Jennifer Ernst presented at DealFlow Events’ PIPEs Conference.
- Two United States Patent and Trademark Office (USPTO) patent applications were filed in 2025: one concerning TLR5 agonist applications in cancer immunotherapy and another for non-invasive cervical vagus nerve stimulation (ncVNS).
Financial and strategic aspects
| Metric | Value |
|---|---|
| Share price (Dec 23, 2025) | $2.27 (+25.41% on Dec 22, 2025) |
| 52-Week range | $1.47 – $15.64 |
| Volume (Dec 22, 2025) | 10,529,943 shares |
| Market capitalization | $3.20 million |
| Revenue (TTM) | $482,000 |
| Net income (TTM) | –$7.55 million |
| Cash and equivalents (MRQ) | $3.45 million |
| Price/sales (TTM) | 3.05 |
| Price/book (MRQ) | 0.57 |
Proceeds from the equity offerings will fund ongoing research and development (R&D), clinical trials, and commercial expansion. The integration of in-house cGMP capabilities aims to reduce development costs and timelines for Entolimod™ and other pipeline candidates. Velocity Bioworks™ is positioned to generate revenue from third-party manufacturing while supporting Tivic’s own biologics programs.
Market position and industry context
Tivic operates in the healthcare sector’s medical appliances and equipment industry, specializing in bioelectronic medicine. Its flagship product, ClearUP®, is an FDA-approved handheld device for sinus pain relief. With a Beta of 1.98, the stock exhibits above-average volatility compared to market norms. Tivic’s dual platform of non-drug bioelectronic devices and immunotherapeutics differentiates it from traditional device manufacturers and pharmaceutical peers, potentially leading to partnerships in clinical, retail, and governmental channels.
tl;dr
On December 12, 2025, Tivic Health Systems filed prospectus supplements to resell over 3.1 million common shares and up to 8,400 Series B Preferred shares, extending its Purchase Agreement to December 9, 2026. A shareholder vote is scheduled by March 9, 2026, to adjust conversion terms. The company acquired cGMP manufacturing assets to support its Entolimod™ BLA and launched Velocity Bioworks™ for CDMO services. Tivic’s share price closed at $2.27 on December 23, 2025, following a 25.41% gain, as management advances both its bioelectronic and immunotherapeutics pipelines toward clinical and regulatory milestones.